Methods of using IGFIR and ABL kinase modulators
US8222256B2 · kind B2 · utility
28Cited by
3References
6Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 3, 2007 |
| Grant date | Jul 17, 2012 |
| Priority date | — |
| Expiry date | Dec 30, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods of treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell transplantation, and one or more chemotherapeutic agent(s).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.